Chief Executive Officer, Hox Therapeutics Ltd, Non-Executive Director at Nuformix Plc and Novai Ltd.

Karl has over 25 years of experience working in senior roles in the life sciences industry. Karl graduated with a BSc from University College, Dublin, followed by MPhil & PhD degrees in pharmacology from the University of Cambridge and a MSc in finance from London Business School. He spent 12 years as a highly regarded sell-side life sciences research analyst, researching and helping finance companies across the UK, Europe, USA and Canada. Since then, primarily in CFO roles, he has focused on corporate development, and has a successful track record of devising and implementing M&A and finance projects, delivering value across all aspects of business strategy, highlights include the sale of Minster pharmaceuticals plc to Proximagen plc, multiple financings to support a new strategy for Pharming Group NV and leadership of M&A deals at Vectura Group plc. Karl is currently CEO at Hox Therapeutics Ltd and is a Non-Executive Director at Nuformix Plc and Novai Ltd.


20 May 2021